Global injury associated with blepharoplasty is rare but serious, study suggests

News
Article

Study investigators found that the injuries ranged from deep thermal burns to full-thickness corneal or scleral lacerations, with one case of traumatic cataract.

Patient's eyelid being prepped for blepharoplasty procedure Image credit: AdobeStock/RabizoAnatolii

Image credit: AdobeStock/RabizoAnatolii

Blepharoplasty is a frequently performed ophthalmic surgery. As with any procedure, even the commonly performed ones, there are associated adverse events. For blepharoplasty, these include infection, bleeding, and excessive or incomplete fat removal among others.

First author Benjamin Meyer, MD, and colleagues reported that global injuries, although rare, also can occur and urged that they be addressed promptly.1 He is from the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.

In this study, the authors reported a case series and literature review with a total of 16 cases of global injury following blepharoplasty.

The investigators found that the injuries ranged from deep thermal burns to full-thickness corneal or scleral lacerations, with 1 case of traumatic cataract.

“The median time from surgery to symptom onset was 1 day, with a concerning median delay of 7 days to presentation to an ophthalmologist. Visual outcomes were generally poor, with nearly all patients experiencing permanent visual morbidity,” they reported.

In addition, endophthalmitis developed in 3 cases that were reported in the systemic review that occurred following perforating scleral injuries.

A comparison of penetrating and perforating injuries showed no differences in the visual outcomes.

Meyer and colleagues called for increased vigilance for globe injuries that require prompt ophthalmologic evaluation following blepharoplasty. They especially emphasized the delayed presentation and the degree of the visual morbidity

“The study advocates for improved practitioner training in recognizing and managing these complications and underscores the importance of patient education regarding the potential risks and the necessity of timely postoperative care,” they concluded.

Reference:
  1. Meyer BI, Shoji MK, Zamani KA, et al. Beyond the surface: a systematic review of perforating and penetrating globe injuries from blepharoplasty. Ophthal Plast Recons. 2024;40:374-379;DOI: 10.1097/IOP.0000000000002625
Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.